A Phase II, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Autologous cultured kidney tissue cells (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors RegenMedTX
- 09 Mar 2018 Last checked against ClinicalTrials.gov record.
- 03 Mar 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 03 Mar 2018 Planned primary completion date changed from 1 Oct 2020 to 1 May 2021.